Hepatocellular Carcinoma Drugs Market Expansion Continues, with Forecast Valuation of $1.72 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Hepatocellular Carcinoma Drugs Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent years, there has been a significant upsurge in the size of the hepatocellular carcinoma drugs market. The market is projected to enhance from $1.16 billion in 2024 to about $1.25 billion in 2025, with a compound annual growth rate (CAGR) of 7.6%. The growth experienced during the historic period was primarily due to a spike in disease prevalence, improvements in cancer research, enhanced global healthcare infrastructural facilities, regulatory clearances, along with awareness campaigns and initiatives towards early diagnosis.

Hepatocellular Carcinoma Drugs Market Size Forecast: What's the Projected Valuation by 2029?
Anticipated to experience robust expansion in the forthcoming years, the market size for drugs treating hepatocellular carcinoma is predicted to reach "$1.72 billion in 2029, growing at a compound annual growth rate (CAGR) of 8.4%. The projected growth during the forecast period can be credited to the progress in targeted therapies, rise in the aging population, personalization in healthcare, and the worldwide enlargement of treatment accessibility. The prediction period is marked by trends such as the availability of innovative therapies, the focus on patient-oriented care, advancements in regulatory matters, the implementation of strategies to combat drug resistance, and joint research efforts.

View the full report here:
https://www.thebusinessresearchcompany.com/report/hepatocellular-carcinoma-drugs-global-market-report

What Are the Drivers Transforming the Hepatocellular Carcinoma Drugs Market?
The prevalence of hepatocellular carcinoma (HCC) is on the rise, which is anticipated to spur the expansion of the market for hepatocellular carcinoma drugs. HCC, the most frequent type of liver cancer, is a principal malignant disease stemming from hepatocyte cells, the chief liver cells. The higher instances of HCC are usually associated with hepatitis B or C, and cirrhosis. With the continuing surge in HCC cases, there is a growing need for effective drugs to fight this disease. The American Cancer Society, a US-based voluntary health organization striving to eradicate cancer, reported in 2023 that the freshly diagnosed liver cancer cases in females in the United States grew from 12,660 in 2022 to 13,230 in 2023. Thus, the escalating prevalence of hepatocellular carcinoma is fuelling the expansion of the hepatocellular carcinoma drug market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10809&type=smp

What Are the Key Trends Driving Hepatocellular Carcinoma Drugs Market Growth?
Key players in the hepatocellular carcinoma drugs market are focusing on creating laboratory-engineered molecules like monoclonal antibodies (mAb) to expand their customer reach, enhance sales, and boost their revenue. A monoclonal antibody (mAb) is made in a lab, designed to imitate the immune system's capability to combat harmful pathogens such as bacteria or viruses. For instance, AstraZeneca PLC, a pharmaceutical and biotechnology company based in the UK, revealed in October 2022 that the US Food and Drug Administration (FDA) had approved Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) for the treatment of adult patients with hepatocellular carcinoma (HCC). Imfinzi (durvalumab) is a unique human monoclonal antibody that binds effectively to the PD-L1 protein, impeding its interaction with PD-1 and CD80 proteins. This interference thwarts the tumor's ability to evade the immune system, removing the restriction on immune responses. Imjudo (tremelimumab), on the other hand, is a human monoclonal antibody that specifically targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) activity. By inhibiting CTLA-4 activity, Imjudo encourages T-cell activation, leading to a strengthened immune response against cancer and facilitating the death of cancer cells.

Which Segments in the Hepatocellular Carcinoma Drugs Market Offer the Most Profit Potential?
The hepatocellular carcinoma drugs market covered in this report is segmented -

1) By Type: Brachytherapy, Chemotherapy
2) By Drug Class: PD-1/PD-L1 Inhibitors, Tyrosine Kinase Inhibitors
3) By End User: Hospitals, Clinics, Cancer Rehabilitation Centers, Ambulatory Surgical Centers

Subsegments:
1) By Brachytherapy: Radioactive Seed Implants, Balloon-Activated Brachytherapy, SIRT (Selective Internal Radiation Therapy)
2) By Chemotherapy: Systemic Chemotherapy, Targeted Therapy Agents, Combination Chemotherapy Regimens, Adjuvant Chemotherapy

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10809&type=smp

Which Firms Dominate the Hepatocellular Carcinoma Drugs Market by Market Share and Revenue in 2025?
Major companies operating in the hepatocellular carcinoma drugs market include AbbVie Inc., Amgen Inc., Bayer AG, Bristol-Myers Squibb Company, Eisai Co.Ltd., Eli Lilly and Company, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, Gilead Sciences Inc., Exelixis Inc., Ipsen Pharma Biotech SAS, AstraZeneca plc, BeiGene Ltd., Ono Pharmaceutical Co. Ltd., Roche Holdings AG, Sanofi S.A., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Otsuka Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hengrui Medicine Co. Ltd., CSPC Pharmaceutical Group Limited, Hutchison China MediTech Limited, Jiangsu Hengrui Medicine Co. Ltd.

Which Regions Offer the Highest Growth Potential in the Hepatocellular Carcinoma Drugs Market?
North America was the largest region in the hepatocellular carcinoma drug market in 2024. The regions covered in the hepatocellular carcinoma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10809

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.